|
Sunday, 08/01/2010
|
Novel Phase I Design for Oncology Research
Linda Sun, Merck & Co., Inc.; Keaven M. Anderson, Merck Research Laboratories; Lisa Lupinacci, Merck & Co., Inc.; Yevgen Tymofyeyev, Merck & Co., Inc.
2:05 PM
|
Partnership in New Drug Developments
Ji Zhang, Sanofi-Aventis; Hui Quan, sanofi-aventis; Alex Boddy, sanofi-aventis; Peng-Liang Zhao, sanofi-aventis; Stan Young, National Institute for Statistical Science
2:25 PM
|
Better Learning About the MTD in Phase I Oncology Trial: A Case Study Implementing Bayesian Design Based on Continuous Reassessment Method
Inna Perevozskaya, Pfizer Inc.
2:25 PM
|
Optimal and Efficient Designs for Generalized Linear Models
John Stufken, The University of Georgia
2:35 PM
|
Analysis of the Variances of American Community Survey Estimates of the Group Quarters Population
John Matthew Jordan, U.S. Census Bureau; Michael Beaghen, U.S. Census Bureau
2:45 PM
|
Efficient Designs for a Noncompensatory Choice Model
Qing Liu, University of Wisconsin-Madison
2:45 PM
|
Adaptive Designs in Dose-Finding Oncology Drug Combination Trials
Yuehui Wu, GlaxoSmithKline; Bingming Yi, GlaxoSmithKline; Yanmei Xu, GlaxoSmithKline
2:45 PM
|
Robust Testing in Matched Case-Control Association Studies
Yong Zang, The University of Hong Kong; Wing Kam Fung, The University of Hong Kong; Gang Zheng, National Institutes of Health
2:50 PM
|
Multistratum Fractional Factorial Designs
Ching-Shui Cheng, University of California, Berkeley
3:05 PM
|
Evaluation of Dose-Finding Designs: On the Interplay Between Theory and Simulation
Assaf P. Oron, University of Washington; Peter Hoff, University of Washington
3:05 PM
|
Design and Analysis of a Simulation Study on MPLS Network
Wenbiao Zhang, Insurance Corporation of British Columbia; Pranesh Kumar, University of Northern British Columbia
3:05 PM
|
On the Optimal Allocation of Time Points of Heterogeneous Time-Structured Data
Martijn P.F. Berger, Maastricht University
3:20 PM
|
Expect the Unexpected: Bayesian Adaptive Dose-Finding Design in Proof-of-Concept Study
Feng Liu, GlaxoSmithKline
3:25 PM
|
Methods for Detecting Interactions Between Genetic Polymorphisms and Prenatal Environment Exposure with a Mother-Child Design
Shuang Wang, Columbia University; Tian Zheng, Columbia University; Stephen Chanock, National Cancer Institute; Wieslaw Jedrychowski, Jagiellonian University; Frederica Perera, Columbia University
3:25 PM
|
Bayesian Adaptive Designs for Dose Escalation Studies
Anna Elizabeth McGlothlin, Eli Lilly and Company
4:05 PM
|
Reliability Data Analysis for Designed Experiments
Laura June Freeman, Virginia Tech; Geoffrey Vining, Virginia Tech
4:05 PM
|
Phase I Studies: Goals, Patient Selection, and Implications for Design
Paul H. Frankel, City of Hope; Stephen Shibata, City of Hope; Susan Groshen, University of Southern California, Norris; Jeffrey Longmate, City of Hope; Stella Khoo, City of Hope; Edward Newman, City of Hope
4:05 PM
|
An Evaluation of a Simon 2-Stage Phase II Clinical Trial Design Incorporating Continuous Toxicity Monitoring
Herman Ray, University of Louisville; Shesh Rai, University of Louisville
4:20 PM
|
Two-Stage Adaptive Design for Bioequivalence: Methods and Application
Yi-Lin Chiu, Abbott Global Pharmaceuticals Research and Development; Yannis Jemiai, Cytel Inc.; Charles Locke, Abbott Laboratories; Pralay Senchaudhuri, Cytel Inc.
4:25 PM
|
Integrating Sample Designs for Environmental Industry and Occupational Employment Surveys
Shail Jain Butani, Bureau of Labor Statistics; David Salvatore Piccone, Bureau of Labor Statistics; Edwin L. Robison, Bureau of Labor Statistics
4:35 PM
|
Exact Two-Stage Designs for Phase II Clinical Trials with Rank-Based Endpoints
Gregory E. Wilding, State University of New York at Buffalo; Guogen Shan, State University of New York at Buffalo; Alan Hutson, State University of New York at Buffalo
4:35 PM
|
Optimal Designs for Toxicology Studies with Multiple Responses and Multiple Stressors
Edward L. Boone, Virginia Commonwealth University; David Edwards, Virginia Commonwealth University; Shuchi Jain, Virginia Commonwealth University
4:35 PM
|
Using Bayesian Adaptive Designs for FDA Event Safety Studies
Jason Connor, Berry Consultants, LLC; Scott Berry, Berry Consultants, LLC; Donald Arthur Berry, MD Anderson Cancer Center
4:45 PM
|
Design of an Observational Study to Evaluate the Effectiveness of IAP During Labor Against Early Onset Disease in Newborns
Donald B. Rubin, Harvard University; Stephanie J. Schrag, CDC; Elizabeth R. Zell, CDC
4:50 PM
|
Interval-Censored Time-to-Event Data in Clinical Trials: Analyzing and Designing
Xing Sun, Merck & Co., Inc.; Cong Chen, Merck & Co., Inc.
4:50 PM
|
Empirical Comparison of Different Drug Safety Signal Detection Assays Based on Incident User Designs
Maurice Alan Brookhart, Brigham and Women's Hospital/Harvard Medical School; Eric Brinsfield, SAS Institute
4:55 PM
|
A Bayesian Dose-Finding Design Adapting to Efficacy and Tolerability Response
S. Krishna Padmanabhan, Pfizer Inc.; Scott Berry, Berry Consultants, LLC; Vladimir Dragalin, Pfizer Inc.; Michael Krams, Pfizer Inc.
5:05 PM
|
Design of Nonrandomized Medical Device Trials Based on Subclassification Using Propensity Score Quintiles
Greg Maislin, Biomedical Statistical Consulting; Donald B. Rubin, Harvard University
5:25 PM
|
|
Monday, 08/02/2010
|
CANCELLED: What You Always Wanted to Know About Computer Experiments but Were Afraid to Ask
William Notz, The Ohio State University
|
Assessing a Hybrid Introductory Statistics Class
Kathy Gray, California State University, Chico
|
Meta-Analyses of Multiple Baseline Time Series Design Intervention Models for Dependent and Independent Series
Oluwagbohunmi Adetunji Awosoga, University of Lethbridge; Joseph W. McKean, Western Michigan University; Bradley E. Huitema, Western Michigan University
|
Statistical Considerations on Validating Microarray Platform in Clinical Development
Guang (Gary) Chen, Merck & Co., Inc.; Christopher Ramsborg, Merck & Co., Inc.; Yue Wang, Merck & Co., Inc.; Miho Kibukawa, Merck & Co., Inc.; Joel A. Klappenbach, Merck & Co., Inc.
|
A Simulation to Evaluate the Impact of Design on Model-Based Methods for National Health and Nutrition Examination Survey (NHANES) Data Linked with Environmental Exposures
Jennifer Parker, National Center for Health Statistics; Lester Randolph Curtin, CDC; Van Parsons, National Center for Health Statistics
|
A Simulation Study to Evaluate Dose-Response in Dose-Titration Clinical Trials: A Dynamic Linear Mixed Effect (DLME) Modeling Approach
Xu Steven Xu, Johnson & Johnson; Min Yuan, Fudan University, China; Julia Wang, Johnson & Johnson; Partha Nandy, Johnson & Johnson
|
Designing Experiments for Biopharmaceutical Process Development
Julia O'Neill, Merck & Co., Inc.
|
Sample Weights in Survey Data
Katie Genadek, University of Minnesota
|
Sequential Application of a Third-Order Test Design in Six Dimensions Incorporating an Orthogonality Constraint
William Line, DOES Institute; Mike Morton, DOES Institute; Norman Draper, University of Wisconsin-Madison
|
Using Imperfect Fidelity Measures to Improve Statistical Inferences About Educational Interventions
Xin Sun, Southern Methodist University
|
Implementation of EWOC (Escalation With Overdose Controls) Adaptive Dose-Finding Design in a Phase IIA Clinical Trial
Catherine Bresee, Oschin Comprehensive Cancer Institute; Amir Steinberg, Oschin Comprehensive Cancer Institute; Jeremy Rudnick, Oschin Comprehensive Cancer Institute; Andre Rogatko, Oschin Comprehensive Cancer Institute
|
Modernizing a Survey: A Case Study with the Census of Finance Companies
Lisa Chen, Federal Reserve Board
|
Comparisons of Methods in Phase I Dose-Escalation Clinical Trial Designs
Liping Huang, Bayer HealthCare Pharmaceuticals
|
A General Framework of Adaptive Designs for Early-Phase Oncology Clinical Trials
Lixin Lang, Bristol-Myers Squibb; Ralph Raymond, Bristol-Myers Squibb
|
Increasing Efficiency of Conservation Application: Conservation Design for Rare Birds in the Upper Midwestern United States
Wayne E. Thogmartin, U.S. Geological Survey
8:35 AM
|
Estimating the Agreement and Diagnostic Accuracy of Two Diagnostic Tests When One Test Is Conducted on Only a Subsample of Specimens
Hormuzd A. Katki, National Cancer Institute; Yan Li, The University of Texas at Arlington; Philip E. Castle, National Cancer Institute
8:35 AM
|
Sample Size and Power Considerations for Futility Trial Design: Buying Power vs. Spending Beta
Thomas Dobbins, Merck & Co., Inc.
8:50 AM
|
Response and Mode Switching in a Sequential Mixed-Mode Design
Rachel Levenstein, University of Michigan; James Lepkowski, University of Michigan; Jennifer Barber, University of Michigan
9:05 AM
|
More Efficient Experimental Designs for CNV Studies Utilizing aCGH Technology
Jeanette Eckel-Passow, Mayo Clinic; Shannon McDonnell, Mayo Clinic; Shaun Riska, Mayo Clinic; Erik Thorland, Mayo Clinic; Eric Klee, Mayo Clinic
9:05 AM
|
Two-Stage Adaptive Design for Case-Control Genetic Association Studies
Lihan Yan, FDA
9:15 AM
|
Adaptive Factorial Designs for Combination Therapy in Oncology
Donald Arthur Berry, MD Anderson Cancer Center
9:15 AM
|
Variability Exploration in Six Phase III Diabetes Clinical Trials: Implications for Research Studies
Hua Guo, Merck Research Laboratories; Bret Musser, Merck Research Laboratories
9:20 AM
|
Logistic Generalized Regression (LGREG) Estimator in Cluster Samples
Timothy Kennel, U.S. Census Bureau
9:20 AM
|
Sample-Size Estimation for Detecting Trends in Repeated Surveys
Mark C. Otto, U.S. Fish and Wildlife Service
9:20 AM
|
Outcome-Dependent Sampling for Continuous Longitudinal Response Data
Jonathan Schildcrout, Vanderbilt University; Paul J. Rathouz, The University of Chicago; Patrick Heagerty, University of Washington
9:20 AM
|
Projection Array--Based Designs for Computer Experiments
Jason Loeppky, The University of British Columbia; Leslie Moore, Los Alamos National Laboratory; Brian Williams, Los Alamos National Laboratory
9:25 AM
|
Making a Difference with Software for Design and Analysis of Experiments
Bradley Jones, SAS Institute
9:25 AM
|
EWOC Online: A Novel Web Application for Computing a Bayesian Phase I Design Method for Dose-Finding with Escalation with Overdose Control
Dror Berel, Cedars-Sinai Medical Center; Andre Rogatko, Oschin Comprehensive Cancer Institute
9:35 AM
|
Optimal Two-Stage Phase II Design Utilizing Partial Information for Long-Term Endpoints
Bo Huang, Pfizer Inc.; Enayet Talukder, Pfizer Inc.; Neal Thomas, Pfizer Inc.
9:35 AM
|
An Arcsin Limit Theorem of D-Optimal Designs for Weighted Polynomial Regression
Fu-Chuen Chang, National Sun Yat-sen University; Jhong-Shin Tsai, National Sun Yat-sen University
9:35 AM
|
Evaluation of Common Statistical Methods in Randomized Delayed-Start Design of Progression Disease Clinical Trials
Bongin Yoo, Bristol-Myers Squibb; Thomas Kelleher, Bristol-Myers Squibb
9:35 AM
|
Constructing Optimal Space-Filling Designs with Large Run Sizes
Chunfang Devon Lin, Queen's University
9:50 AM
|
Two-Stage Designs with Additional Futility Tests for Phase II Clinical Trials with Heterogeneous Patient Populations
Myron N. Chang, University of Florida; Sin-Ho Jung, Duke University
10:05 AM
|
Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges
Daniel Sargent, Mayo Clinic; Sumithra Mandrekar, Mayo Clinic
10:35 AM
|
Computer-Automated Model Selection: Friedman and Schwartz Revisited
Neil R. Ericsson, Federal Reserve Board
10:35 AM
|
Do Comparison Group Methods Replicate Experimental Impact Estimates in an Education Setting? A Charter School Evaluation Example
Kenneth Fortson, Mathematica Policy Research, Inc.; Natalya Verbitsky-Savitz, Mathematica Policy Research, Inc.; Philip Gleason, Mathematica Policy Research, Inc.; Emma Ernst, Mathematica Policy Research, Inc.
10:35 AM
|
Comparison of Characteristics of Cell-Only, Cell-Mostly, and Landline Households
Wei Zeng, NORC; Benjamin Skalland, NORC; Karen Wooten, National Center for Immunization and Respiratory Diseases; Meena Khare, National Center for Health Statistics
10:35 AM
|
Achieving the Benefits of Both an Internal Pilot and Interim Analysis in Small Samples
John A. Kairalla, University of Florida; Keith E. Muller, University of Florida; Christopher S. Coffey, The University of Iowa
10:35 AM
|
Adaptive Bayesian Calibration of Computer Models Using Sequential Monte Carlo
Gardar Johannesson, Lawrence Livermore National Laboratory
10:35 AM
|
Incorporating Sampling Designs Into a Grade of Membership (GoM) Model
Marnie Bertolet, University of Pittsburgh
10:50 AM
|
Dual-Frame Sample Sizes (RDD and Cell) for Future Minnesota Health Access Surveys
Steven Pedlow, NORC; Kanru Xia, NORC; Michael Davern, NORC
10:55 AM
|
Design and Operational Changes for REACH US
Rachel Harter, NORC
11:00 AM
|
Exact D-Optimal Designs for Linear Log Contrast Models
Mong-Na Lo Huang, National Sun Yat-sen University; Miao-Kuan Huang, National Formosa University; Baisuo Jin, University of Science and Technology of China
11:05 AM
|
Balanced and Partially Balanced Incomplete Block Designs with Autocorrelation Errors
Xiaohua (Holly) Shu, Temple University; Damaraju Raghavarao, Temple University
11:05 AM
|
Computational Issues in Bayesian Design of Life Tests
Refik Soyer, The George Washington University
11:15 AM
|
Sample Size Requirement in Clustered Matched-Pair Design for Noninferiority Test
Jun-mo Nam, National Cancer Institute
11:20 AM
|
Spatial Multivariate Design in the Plane
Jie Li, Eli Lilly and Company; Dale Zimmerman, The University of Iowa
11:20 AM
|
The Influence of Prior Experiences in Managing Current and Future Risks During Survey Transition Points on the National Survey on Drug Use and Health (NSDUH)
Joe Gfroerer, Substance Abuse and Mental Health Services Administration; Jonaki Bose, Substance Abuse and Mental Health Services Administration
11:25 AM
|
Simplifying Objective Functions and Avoiding Stochastic Search Algorithms in Spatial Sampling Design
Gunter Spöck, University Klagenfurt; Jürgen Pilz, University Klagenfurt; Zhengyuan Zhu, Iowa State University
11:35 AM
|
Designing Noninferiority Study: A New Perspective
George Y.H. Chi, Johnson & Johnson; Gang Li, Johnson & Johnson; Qing Liu, Johnson & Johnson
11:35 AM
|
Optimal Serial Dilutions Designs for Drug Discovery Experiments
Alexander Donev, University of Manchester; Randy Tobias, SAS Institute
2:05 PM
|
Applications of 'Learn' Phase Adaptive Designs
Jose Carlos Pinheiro, Johnson & Johnson; Chyi-Hung Hsu, Novartis Pharmaceuticals Corporation
2:05 PM
|
Efficient Weighting Approaches for Analysis of Population-Based Case-Control Studies with Complex Sampling Designs
Victoria Landsman , National Cancer Institute ; Barry I. Graubard, National Cancer Institute
2:05 PM
|
Adaptive Design for Sample Size Re-estimation in a Medical Device Trial of Spinal Cord Stimulation
Nitzan Mekel-Bobrov, Boston Scientific Corporation
2:05 PM
|
Nonparametric Multiple Comparison Procedures for Unbalanced Designs
Xin Gao, York University
2:05 PM
|
Innovative Imputation Techniques Designed for the Agricultural
Michael Robbins, National Institute of Statistical Sciences
2:25 PM
|
Statistical Design for a Small Serial Dilution Series
Daniel Zelterman, Yale University
2:25 PM
|
Adaptive Sample Size Re-estimation When Interim Results Are Promising
Cyrus R. Mehta, Cytel Inc.
2:25 PM
|
Testing a Primary and a Secondary Endpoint in a Group Sequential Design
Ajit C. Tamhane, Northwestern University; Cyrus R. Mehta, Cytel Inc.; Lingyun Liu, Cytel Inc.
2:25 PM
|
Hypothesis Testing of Treatment Policies in Two-Stage Randomization Designs
Xiang Guo, sanofi-aventis (China); Anastasios Tsiatis, North Carolina State University
2:30 PM
|
Guiding Clinicans Through the EffTox Model
Meagan E. Spychala, Rho, Inc.
2:35 PM
|
Stratification of a Sampling Frame with Auxiliary Data Into Piecewise Linear Segments by Means of a Genetic Algorithm
Joseph James Barth, U.S. Census Bureau; Yang Cheng, U.S. Census Bureau
2:35 PM
|
An Adaptive Noninferiority Study
Pilar Lim, Johnson & Johnson; Qing Liu, Johnson & Johnson; Rosanne Lane, Johnson & Johnson; Barry Schwab, Johnson & Johnson; Allan Sampson, University of Pittsburgh
2:45 PM
|
Design and Analysis of Discrete-Time Survival Studies with Pooled Biomarker Assessment
Paramita Saha, National Institute of Environmental Health Sciences; Clarice R. Weinberg, National Institute of Environmental Health Sciences
2:45 PM
|
High-Dimensional Repeated Measures Under Non-Normality
Edgar Brunner, University of Goettingen; Hans-Joachim Helms, University of Goettingen
2:45 PM
|
Comparing Vaccination Estimates from Four Survey Designs: Vaccination Estimates from RDD, RDD+Cell, ABS, and Area Probability Sampling
Martin Barron, NORC; Karen Wooten, National Center for Immunization and Respiratory Diseases; Beth Taylor, National Center for Health Statistics
2:45 PM
|
Variance Estimation for Decision-Based Estimators with Application to the Annual Survey of Public Employment and Payroll
Yang Cheng, U.S. Census Bureau; Slud Eric, University of Maryland; Carma Hogue, U.S. Census Bureau
2:50 PM
|
Case-Parent Triad Studies of Genetic Association and Gene-Gene Interaction in the Presence of Missing Data
Tracy L. Bergemann, University of Minnesota; Matthew Deyo-Svendsen, University of Minnesota
2:50 PM
|
Statistical Work in Nano-Material Research
C.F. Jeff Wu, Georgia Institute of Technology
3:05 PM
|
Optimal Designs for Low-Dose Linear Extrapolation in Carcinogenesis Experiments
Melvin Slaighter Munsaka, Takeda Global Research & Development Center, Inc.
3:05 PM
|
Evaluation of Design Parameters for an Adaptive Seamless Phase 2b/3 Trial
Susan Y. Zhou, CDER/FDA; Greg Soon, CDER/FDA; Xiao Ding, CDER/FDA; JungYeon Park, CDER/FDA; EunYoung Kim, CDER/FDA; Sue-Jane Wang, FDA
3:05 PM
|
Alternative Sample Approach for the Annual Survey of Public Employment and Payroll
Casey Corcoran, U.S. Census Bureau; Yang Cheng, U.S. Census Bureau
3:05 PM
|
Comparison of Influenza Vaccination Rates in Cell-Only, Cell-Mostly, and Landline Households in the National 2009 H1N1 Flu Survey
Nicholas Davis, NORC; Kennon R. Copeland, NORC; Margrethe Montgomery, NORC; James A. Singleton, National Center for Immunization and Respiratory Diseases
3:05 PM
|
Incorporating Nonresponse Follow-Up Into a Main Survey Data Set
Shin-Jung Lee, University of Michigan; James Lepkowski, University of Michigan; Kristen Olson, University of Nebraska-Lincoln; Dandan Zhang, Westat
3:20 PM
|
Design and Analysis of Bioassay Experiments, Risk Issues
Michael E. Tarter, University of California, Berkeley
3:25 PM
|
Estimating Incremental Value in Marker Combinations Using a Two-Stage Study Design
Aasthaa Bansal, University of Washington; Margaret Sullivan Pepe, Fred Hutchinson Cancer Research Center
3:35 PM
|
|
Tuesday, 08/03/2010
|
Distance-Constrained Orthogonal Latin Squares for Brain-Computer Interface
Gang Luo, IBM T.J. Watson Research Center; Wanli Min, IBM T.J. Watson Research Center
|
Design, Implementation, and Results for a Bayesian Adaptive Randomization Trial for Targeted Therapy in Lung Cancer
Suyu Liu, MD Anderson Cancer Center; J. Jack Lee, MD Anderson Cancer Center
|
Statistical Issues in Designing Active Control Studies with an Emphasis on Veterinary Medical Issues
Anna B. Nevius, FDA/CVM
|
CANCELLED: Best Practices for Asking Questions on Sexual Orientation on Surveys
Barry Wayne Johnson, IRS; Elizabeth Saewyc, The University of British Columbia
|
Balancing Competing Objectives for a Good Designed Experiment
Christine M. Anderson-Cook, Los Alamos National Laboratory
|
Facilitating Communication About Analysis Data Needs Across Functional Areas
Steven Kirby, MDS Pharma Services
|
Software Design for Functional Data with Multi-Index Arguments
James Owen Ramsay, McGill University
8:35 AM
|
Balancing Informativeness and Ethics in Clinical Trial Design
Valerii Fedorov, GlaxoSmithKline
8:35 AM
|
Disparity-Aided Robust and Efficient Inference for Adaptive Designs with Covariates
Anand Vidyashankar, George Mason University
8:35 AM
|
The Global Adult Tobacco Survey (GATS): Sample Design and Related Methods
William D. Kalsbeek, The University of North Carolina at Chapel Hill; J. Michael Bowling, The University of North Carolina at Chapel Hill; Krishna M. Palipudi, CDC
8:35 AM
|
Evaluation of Health Care Utilization Data from the National Survey on Drug Use and Health
Jonaki Bose, Substance Abuse and Mental Health Services Administration; Joe Gfroerer, Substance Abuse and Mental Health Services Administration; Michael Pemberton, RTI International
8:55 AM
|
Estimation of Treatment Effect Following a Clinical Trial with Adaptive Design
Xiaolong Luo, Celgene Corporation; Peter Ouyang, Celgene Corporation
9:20 AM
|
Sample Design Methodology for Studying Patients Using Registry Data
Shelton M. Jones, RTI International; Lauren A. McCormack, RTI International; Timothy Patrick Johnson, Survey Research Laboratory; Connie L. Hobbs, RTI International; Joseph P. McMichael, RTI International; Steven B. Clauser, National Cancer Institute
9:20 AM
|
Propensity Score Matching in Randomized Clinical Trials
Zhenzhen Xu, University of Michigan; John David Kalbfleisch, University of Michigan
9:20 AM
|
A Frailty-Model-Based Approach to Estimating the Age-Dependent Penetrance Function of a Gene Mutation Using Family-Based Study Designs
Yun-Hee Choi, The University of Western Ontario; Laurent Briollais, Samuel Lunenfeld Research Institute
9:35 AM
|
A Re-examination of the Analysis of Prevalent Cohort Survival Data
Marco Carone, Johns Hopkins Bloomberg School of Public Health; Masoud Asgharian, McGill University; Daniel O. Scharfstein, Johns Hopkins Bloomberg School of Public Health
9:35 AM
|
Admissibility of Naive Estimator Under LINEX Loss in a Two-Stage Design
AnqiI Sun, University of Florida; Mark Yang, University of Florida
10:05 AM
|
Violence Against Women in Developing Countries: Statistical Challenges
Hrishikesh Chakraborty, RTI International
10:35 AM
|
A Bayesian Adaptive Design with Biomarkers for Targeted Therapies
Jens C. Eickhoff, Colorado State University; KyungMann Kim, University of Wisconsin-Madison; Jill M. Kolesar, University of Wisconsin-Madison; Jason R. Gee, Lahey Clinic Medical Center
10:35 AM
|
Address-Based Area Sampling: An Efficient Hybrid Between Address-Based Sampling and Area Sampling
Avinash C. Singh, NORC; Peter K. Kwok, NORC
10:35 AM
|
Survey Measurement of Complex Latent Constructs: An Example from the National Long Term Care Survey (NLTCS)
Elena A. Erosheva, University of Washington
10:35 AM
|
Applying Covariate-Adjusted, Response-Adaptive Randomization to Medical Device Studies
Thomas E. Gwise, FDA; Gene Anthony Pennello, FDA
10:55 AM
|
Comparing Adaptive and Traditional Crossover Designs for Dose-Finding Trials
James A. Bolognese, Cytel Inc.; Nitin R. Patel, Cytel Inc.; Byron Jones, Pfizer Inc.
11:15 AM
|
Adaptive Designs with Sensitive Subgroup Selection
Yan Daniel Zhao, Eli Lilly and Company; Alex Dmitrienko, Eli Lilly and Company
11:15 AM
|
Multiple Imputation of Disease Status Based on a Two-Phase Sample Design
Steven G. Heeringa, University of Michigan
11:15 AM
|
Iterative Weighting Procedures for School Surveys: Trimming and Raking as One Algorithm
Ronaldo Iachan, ICF Macro; James G. Ross, ICF Macro; Mirna Moloney, ICF Macro
11:20 AM
|
Sample-Size Calculation for Time-to-Event Outcome with Treatment Lag Effect
Yulei Zhang, Columbia University; Tai-Tsang Chen, Bristol-Myers Squibb/Columbia University
11:20 AM
|
I-SPY2: Identifying Biomarker Signatures for Therapeutic Agents in Neoadjuvant Breast Cancer
Donald Arthur Berry, MD Anderson Cancer Center; Kyle Wathen, MD Anderson Cancer Center; Nebiyou Bekele, MD Anderson Cancer Center; Laura Esserman, University of California, San Francisco
11:35 AM
|
Multistage-mutiphase BIB Designs
Dr. Md. Shamsuddin, King Abdulaziz University; Mian Arif Shams Adnan, Jahangirnagar University
11:50 AM
|
Optimal Crossover Designs for PK Studies
Sergei Leonov, GlaxoSmithKline; Valerii Fedorov, GlaxoSmithKline; Byron Jones, Pfizer Inc.
11:55 AM
|
The Design of the Canadian Child Restraint Survey
Jean-Francois Lecuyer, Transport Canada; Aline Chouinard, Transport Canada
12:05 PM
|
A Hybrid Geometric Select-and-Test Design Based on Treatment Failure Time and Toxicity
Peter F. Thall, MD Anderson Cancer Center
2:05 PM
|
Noninferiority Trial Designs for Odds Ratios and Risk Differences
Joan Hilton, University of California, San Francisco
2:05 PM
|
Future Developments in Experimental Design
Douglas C. Montgomery, Arizona State University; Rachel T. Johnson, Naval Postgraduate School; Peter Goos, University of Antwerp
2:05 PM
|
Multiple Frame Sample Design and Estimation for the 2008 National Sample Survey of Registered Nurses - Theory, Implementation, and Assessment
Ralph DiGaetano, Westat; Jim Green, Westat; Jay Clark, Westat; Marshall Fritz, U.S. Department of Health and Human Services
2:05 PM
|
Sampling and Weighting Issues in the National Immunization Survey Evaluation Study
Kimball Jonas, U.S. Census Bureau
2:05 PM
|
Nonparametric Test of Treatment Effects When Design Plans Are Combined
Yvonne M. Zubovic, Indiana University Purdue University Fort Wayne; Chand Chauhan, Indiana University Purdue University Fort Wayne
2:20 PM
|
Overall FDR Control in a Two-Stage Adaptive Design
Jingjing Chen, Temple University; Sanat K. Sarkar, Temple University
2:20 PM
|
Who Needs Bayesian Phase I Trials?
Rick Chappell, University of Wisconsin-Madison
2:30 PM
|
Optimal Designs for Dose-Finding Studies
Frank Bretz, Novartis Pharma
2:30 PM
|
Generalized Hypothesis Testing in Interim Treatment Selection with a Flexible Selection Margin
Yujun Wu, Sanofi-Aventis; Peng-Liang Zhao, sanofi-aventis
2:35 PM
|
Recent History Functional Linear Models for Sparse Longitudinal Data
Kion Kim, Penn State; Damla Senturk, Penn State
2:35 PM
|
Using the National Inpatient Sample (NIS) to Identify Injury Patterns from External Causes of Injury
Heather Watson, Exponent, Inc.; Madhu Iyer, Exponent, Inc.
2:35 PM
|
Functional Clustering in Nested Designs
Abel Rodriguez, University of California, Santa Cruz; David Dunson, Duke University
2:45 PM
|
Pilot Survey Results from the Canadian Survey of Household Spending Redesign
Johanne Tremblay, Statistics Canada; Jenny Lynch, Statistics Canada; Guylaine Dubreuil , Statistics Canada
2:50 PM
|
Improving the Interim Analysis Process in Adaptive Design Trials
Xiaoyin Fan, Merck & Co., Inc.; Mary Varughese, Merck & Co., Inc.
2:50 PM
|
Optimal Designs for Pharmacokinetic Models
Holger Dette, Ruhr-Universität Bochum; Tim Holland-Letz, Ruhr-Universität Bochum
2:55 PM
|
Evaluating Sample Design Issues in the National Compensation Survey
Gwyn R. Ferguson, Bureau of Labor Statistics; Chester Ponikowski, Bureau of Labor Statistics; Joan Coleman, Bureau of Labor Statistics
3:05 PM
|
Interval Estimation in Two-Stage, Drop-the-Losers Clinical Trials with Flexible Treatment Selection
Dan Neal, University of Florida; George Casella, University of Florida; Mark Yang, University of Florida; Samuel S. Wu, University of Florida
3:05 PM
|
Optimal Design in Bioequivalence Studies Analyzed with Nonlinear Mixed Effects Models
France Mentre, Universite Paris-Diderot; Thu Thuy N'guyen, Universite Paris-Diderot/INSERM; Anne Dubois, Universite Paris-Diderot/INSERM; Caroline Bazzoli, Universite Paris-Diderot/INSERM
3:20 PM
|
Challenges in the Design of the Canadian Community Health Survey on Healthy Aging
Leon Jang, Statistics Canada; Martin Provost, Statistics Canada; Adam Sherk, Statistics Canada
3:20 PM
|
Confidence Intervals for the Selected Treatment Effect in Multistage Adaptive Designs
Ionut Bebu, Georgetown University Medical Center; Vladimir Dragalin, Pfizer Inc.; George Luta, Georgetown University
3:20 PM
|
|
Wednesday, 08/04/2010
|
gsDesign Explorer: Easy-to-Use Open Source GUI- and R-Based Group Sequential Design Software
Keaven M. Anderson, Merck Research Laboratories; William Constantine, REvolution Computing; Jason B. Clark, Merck Research Laboratories
|
Gerontologic Biostatistics: Application and Resources
Heather Gwynn Allore, Yale University
|
Optimal Design for Accelerated Degradation Tests for Wiener Degradation Processes with Time-Censoring
Ming-Yung Lee, Providence University; Jen Tang, Purdue University
|
Planning for Nonresponse Bias Analyses
Jill Montaquila, Westat
|
Statistical Issues in Adaptive Design
Wei Zhang, FDA/CVM
|
Bias Correction for Rare Events in Self-Controlled Case Series Design of Vaccine Safety
Chan Zeng, Kaiser Permanente Colorado; Jason M. Glanz, Kaiser Permanente Colorado; Sophia R. Newcomer, Kaiser Permanente Colorado; Stanley Xu, Kaiser Permanente Colorado
|
Efficient Early Phase Designs in Oncology Based on Evidence Synthesis
Jyotirmoy Dey, Novartis Pharmaceuticals Corporation; Wentao Feng, Novartis Pharmaceuticals Corporation
8:35 AM
|
Individually Randomized Group Treatment (IRGT) Trials in HIV/AIDS: How Often Is the Intraclass Correlation Ignored in Design and Analysis?
Sherri L. Pals, CDC; Ryan E. Wiegand, CDC; David Murray, The Ohio State University
8:35 AM
|
On the Use of Historical Information in Selecting Design Type for Phase II Oncology Trials
Yiyi Chen, Oregon Health & Science University; Rongwei (Rochelle) Fu, Oregon Health & Science University; Zunqiu Chen, Oregon Health & Science University
8:35 AM
|
Optimal Survey Design: A Review
Jeffrey Mark Gonzalez, Bureau of Labor Statistics; John L. Eltinge, Bureau of Labor Statistics
8:35 AM
|
Probability-Proportional-to-Size Sampling from a Rare Population
Jens Olofsson, Örebro University
8:50 AM
|
Group-Randomized Trials (GRT) in HIV/AIDS Research: How Often Is the Intraclass Correlation Ignored in Design and Analysis?
Ryan E. Wiegand, CDC; Sherri L. Pals, CDC; David Murray, The Ohio State University
8:55 AM
|
Choice of Estimand, Trial Design, and Trial Conduct
James D. Neaton, University of Minnesota
9:00 AM
|
Forecasting Clinical Trial Enrollment: A Case Study
Zachary Skrivanek, Eli Lilly and Company
9:05 AM
|
Multi-Objective Evolutionary Algorithms for Multivariate Optimal Allocation
Charles D. Day, IRS
9:05 AM
|
Confidence Interval Estimation for Inter-Rater Reliability in a Two-Factor Random-Effects Design
Joseph C. Cappelleri, Pfizer Inc.; Kelly H. Zou, Pfizer Inc.; Carmen Arteaga, Pfizer Inc.; Naitee Ting, Boehringer Ingelheim Pharmaceuticals, Inc.
9:20 AM
|
Bayesian Adaptive Phase II/III Clinical Trial Design Using the Relationship Between Tumor Response and Survival
Donald Arthur Berry, MD Anderson Cancer Center; Haiying Pang, MD Anderson Cancer Center
9:20 AM
|
Assessing Treatment Effect in Clinical Trials with Dichotomous Endpoints
Gang Jia, Merck & Co., Inc.
9:20 AM
|
Optimal Design for Consistent Rating of Classroom Instructions
Yongyun Shin, Virginia Commonwealth University; Stephen W. Raudenbush, The University of Chicago
9:20 AM
|
Sample Redesign of the Annual Fuel Oil and Kerosene Sales Report Survey
Bin Zhang, Energy Information Administration; Pedro Saavedra, ICF Macro; Benita Jean O'Colmain, ICF Macro ; Paula Ellen Mason, Energy Information Administration; Amerine Woodyard, Energy Information Administration
9:20 AM
|
Where Youth Buy Cigarettes: Clustering Patterns and Efficient Design
Christopher Patrick Cummiskey, RTI International; Victoria McNerney, RTI International; Karol Krotki, RTI International
9:35 AM
|
Combining Principal Component Analysis with Parameter Line Searches to Construct Well-Designed Proposal Distributions for Metropolis-Hastings MCMC
David Andrew Kennedy, The University of Chicago; Vanja Dukic, The University of Chicago; Greg Dwyer, The University of Chicago
9:35 AM
|
Adaptive Contact Strategies in Telephone and Face-to-Face Surveys
James Wagner, University of Michigan
10:05 AM
|
On Two-Stage Adaptive Design
Gang Li, Johnson & Johnson; Yining Wang, Johnson & Johnson; Weichung J. Shih, University of Medicine and Dentistry of New Jersey
10:35 AM
|
Key Considerations for Simulations to Optimize Dose-Finding Trials
Natalie Cheung Hall, Eli Lilly and Company
10:35 AM
|
Sequential Experiment Design for Emulator and Predictive Maturity
Brian Williams, Los Alamos National Laboratory; Jason Loeppky, The University of British Columbia; Leslie Moore, Los Alamos National Laboratory
10:35 AM
|
Horvitz-Thompson Variance Weights: Exact vs. Approximate
James R. Chromy, RTI International
10:35 AM
|
Sequential Design of Computer Experiments for Multiobjective Optimization
Joshua Svenson, The Ohio State University; Thomas J. Santner, The Ohio State University
10:50 AM
|
Bayesian Design for Nonrandomized Phase II Oncology Trials
Yanmei Xu, GlaxoSmithKline; Bingming Yi, GlaxoSmithKline
10:55 AM
|
A Statistical Design for Investigating Skin Diffusion-Based Dose Response in Humans
Jihao Zhou, Allergan Pharmaceuticals, Inc.; Thomas Lin, Allergan Pharmaceuticals, Inc.; Susan Guo, Allergan Pharmaceuticals, Inc.; Barbara Scholz, Allergan Pharmaceuticals, Inc.
11:05 AM
|
Comparison of Sequential Designs of Computer Experiments in High Dimensions
Ana Kupresanin, Lawrence Livermore National Laboratory; Gardar Johannesson, Lawrence Livermore National Laboratory
11:05 AM
|
A Bayesian Design for a Proof-of-Concept Study Comparing Rituxan in Combination with a New Drug to Rituxan Alone
Sharon C. Murray, GlaxoSmithKline; John F. Toso, GlaxoSmithKline; John W. Bauman, GlaxoSmithKline;
11:15 AM
|
Covariate-Adjusted Response-Adaptive Randomization Design with Survival Responses
Hongjian Zhu, University of Virginia; Feifang Hu, University of Virginia
11:15 AM
|
Should I Use Gain Scores to Determine Treatment Effect from a Pretest-Posttest Design?: A Simulation Study
Michael Posner, Villanova University; AnneMichele Millar, Mount Saint Vincent University; Philip Yates, California State Polytechnic University, Pomona
11:15 AM
|
Statistical Inference Following an Adaptive Design for Case-Driven Efficacy Study
Xiaoming Li, Merck Research Laboratories; Ivan S.F. Chan, Merck Research Laboratories; Keaven M. Anderson, Merck Research Laboratories
11:20 AM
|
When Science Meets Security
Roy Maxion, Carnegie Mellon University
11:25 AM
|
On the Analysis of Genomewide Association Studies in Family-Based Designs: A Universal, Robust Analysis Approach and an Application to Four Genomewide Association Studies
Bhramar Mukherjee, University of Michigan; Christoph Lange, Harvard School of Public Health
11:35 AM
|
A Bayesian Design with the Time-to-Event Endpoint
Qiong Wang, GlaxoSmithKline
11:35 AM
|
Statistical Aspect of Design and Normalization of Customized Affymetrix Arrays
Shibing Deng, Pfizer Inc.
11:35 AM
|
Robust Probe for the Quantum Pauli Channel
Michael Frey, Bucknell University; Jeffrey Graham, Susquehanna University; Lucas Mentch, Bucknell University; Amy Miller, Muskingum University
11:50 AM
|
A Hybrid Frequentist-Bayesian Approach to a Pilot Study
Nicole Blackman, GlaxoSmithKline
11:55 AM
|
Hierarchical Gaussian Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials
Bradley P. Carlin, University of Minnesota; Brian P. Hobbs, University of Minnesota; Daniel Sargent, Mayo Clinic; Sumithra Mandrekar, Mayo Clinic
2:05 PM
|
Simulation of a Phase III Trial Using Realizations of Posterior Distribution Based on a Phase IIb Trial
A. Lawrence Gould, Merck Research Laboratories
2:05 PM
|
Sequential Design of Phase II--III Cancer Trials
Tze Leung Lai, Stanford University; Philip Lavori, Stanford University; Mei-Chiung Shih, Stanford University
2:05 PM
|
Two Approaches to Design Effects
Matthias Ganninger, Leibniz Institute for the Social Sciences; Sabine Häder, Leibniz Institute for the Social Sciences; Siegfried Gabler, Leibniz Institute for the Social Sciences
2:05 PM
|
Introducing the 2020 Census
Sally Obenski, U.S. Census Bureau; Elaine Reed, Mitre Corporation
2:05 PM
|
Probabilistic Approach to Editing
Maiki Ilves, Örebro University
2:20 PM
|
Nonparametric Regression in Some Nonstandard Sampling Situations
Alan H. Dorfman, Bureau of Labor Statistics
2:30 PM
|
Methodological Challenges in Linking NHANES Biomarker Data with Ambient Air Data and Surrogate Measures of Traffic-Related Air Pollution
Sorina Eftim, University of Maryland; Amir Sapkota, University of Maryland; Jennifer Parker, National Center for Health Statistics
2:35 PM
|
Design Effects and Misspecification Effects for Cross-National Comparisons Where Sample Design Varies Between Countries
Olena Kaminska, University of Essex; Peter Lynn, University of Essex
2:45 PM
|
Operational Design Options for the 2020 Census
James Treat, U.S. Census Bureau; James Treat, U.S. Census Bureau
2:45 PM
|
Gene-by-Environment Interactions in Studies Based on Nuclear Families
Clarice R. Weinberg, National Institute of Environmental Health Sciences; Min Shi, National Institute of Environmental Health Sciences; David Umbach, National Institute of Environmental Health Sciences
2:45 PM
|
Statistical Design, Sampling Weights, and Weight Adjustments of the School Physical Activity and Nutrition (SPAN) Population-Based Surveillance 2009--2010 Study
Adriana Perez, The University of Texas School of Public Health; Deanna M. Hoelscher, Michael & Susan Dell Center for Advancement of Healthy Living; Ralph F. Frankowski, The University of Texas School of Public Health; R. Sue Day, The University of Texas School of Public Health; Eun Sul Lee, Oregon Health & Science University
2:50 PM
|
Case Study: Benefits of an Adaptive Clinical Trial Design in Oncology
Darcy Hille, Merck & Co., Inc.; Christine K. Gause, Merck Research Laboratories; Jason B. Clark, Merck Research Laboratories; Sarah Hoagey, Merck & Co., Inc.; Keaven M. Anderson, Merck Research Laboratories
2:50 PM
|
Is ABS a Viable Alternative to RDD?
Karol Krotki, RTI International
2:50 PM
|
A Nonhomogeneous Hidden Markov Model for Analyzing ChIP-chip Tiling Array Data
Nancy Naichao Wang, Exponent, Inc.; Terence Paul Speed, University of California, Berkeley
2:50 PM
|
Predictive Probability Approach for the Design and Analysis of Response and Toxicity Data in Cancer Clinical Trials
J. Jack Lee, MD Anderson Cancer Center; Guosheng Yin, The University of Hong Kong; Nan Chen, M D Anderson Cancer Center
2:55 PM
|
Robust Transmission Disequilibrium Test for Family Trio Design
Min Yuan, Fudan University, China; Yaning Yang, University of Science and Technology of China; Xin Tian, National Institutes of Health; Gang Zheng, National Institutes of Health
3:05 PM
|
Strategies for Setting Up the Logistics in Early Phase Adaptive Design Clinical Trials
Eva R. Miller, ICON Clinical Research
3:05 PM
|
Online Experimentation: Principles and Practice
Roger Longbotham, Microsoft Corporation; Ji Chen, Microsoft Corporation; Justin Wang, Microsoft Corporation
3:05 PM
|
Statistical Methods for a Phase II Oncology Trial with a GMI Endpoint
Stephanie Ann Kovalchik, University of California, Los Angeles; William Leonard Mietlowski, Novartis Oncology
3:20 PM
|
Alternative Weight Trimming Methods to Estimate Totals in Single-Stage Sample Designs
Kimberly Henry, IRS
3:25 PM
|
|
Thursday, 08/05/2010
|
Adaptive Designs for Dose-Ranging Studies
Vladimir Dragalin, Pfizer Inc.
8:35 AM
|
Sample Size Determination for Two-Stage Equivalence Test
Mi-Chia Ma, National Cheng Kung University; Shang-Bo Ye, National Cheng Kung University
8:35 AM
|
Issues in Cross-Cultural and Comparative Questionnaire Design, Pretesting, and Administration
Gordon Willis, National Cancer Institute
8:35 AM
|
Design Effects for Totals in Multi-stage Samples
Keith Rust, Westat; Pam Broene, Westat
8:35 AM
|
Maximizing the Longitudinal Rate of Change with Multiple Outcome Measures to Improve the Design of Clinical Trials on Alzheimer's Disease
Chengjie Xiong, Washington University
8:35 AM
|
Using Weak and Strong Heredity to Generate Weighted Design Optimality Criteria for Response Surface Designs
Philip Turk, West Virginia University; John Borkowski, Montana State University; Boonorm Chomtee, Kasetsart University
8:50 AM
|
Biomarkers in Clinical Trials in the Development of Biologics and Risk Assessment
Samir Lababidi, FDA
8:50 AM
|
Adjusting for Baseline Measurements in Crossover Studies
Chengcheng Liu, Merck & Co., Inc.; Lingling Han, Merck & Co., Inc.; Xiaodong Li, Merck & Co., Inc.; Peng Sun, Merck & Co., Inc.
8:50 AM
|
Bayesian Adaptive Designs in Practice
Scott Berry, Berry Consultants, LLC; Jason Connor, Berry Consultants, LLC
9:00 AM
|
Study Designs for Evaluating Personal Risk Models
Alice S. Whittemore, Stanford University
9:05 AM
|
Dependent Exposure in a Matched Case-Control Study
Mark Delorey, CDC
9:05 AM
|
Considerations on the Study Design and Analysis of Vulvar and Vaginal Atrophy Studies
Ling Chen, FDA
9:05 AM
|
Some Recent Advances on Quaternary-Code Designs
Frederick Kin Hing Phoa, Academia Sinica
9:05 AM
|
Sequential Tite-CRM: Designing a Two-Dimensional Dose-Finding Trial
Matthew Schipper, University of Michigan; Edgar Ben-Josef, University of Michigan
9:05 AM
|
Cost-Effective Combinatorial Design for Rare-Disease Carrier Screen Using Next-Generation Sequencing Technology
Lingling An, The University of Arizona; Dear Pookhao, The University of Arizona
9:05 AM
|
Modeling Intraclass Correlation in the Design of Cluster-Randomized Trials with Binary Outcomes
Catherine M. Crespi, University of California, Los Angeles; Weng Kee Wong, University of California, Los Angeles
9:15 AM
|
Current Population Survey Correlations Across and Within the 1990/2000 Phase-In/Phase-Out Period
Antoinette Lubich, U.S. Census Bureau; Reid Rottach, U.S. Census Bureau
9:15 AM
|
Optimal Designs for Binary Logistic Regression with a Qualitative Classifier
Karabi Sinha, University of California, Los Angeles
9:20 AM
|
Optimal Design for Multifactor Life-Testing Experiments
Steven E. Rigdon, Southern Illinois University Edwardsville; Douglas C. Montgomery, Arizona State University; Rong Pan, Arizona State University; Connie M. Borror, Arizona State University West
9:20 AM
|
Issues to Consider in Selecting a Response-Adaptive Design for Dose-Finding Experiments
Nancy Flournoy, University of Missouri
9:25 AM
|
How to Handle Placebo Data in Dosing Ranging Studies Using 2-by-2 Crossover Design
Xin Zhao, Merck & Co., Inc.
9:35 AM
|
An Introduction to Presampling Inference II
Stephen Woodruff, Specified Designs
9:50 AM
|
Obtaining Population Representation with an Address-Based Sampling Design
Michael Link, The Nielsen Company; Jennie Lai, The Nielsen Company; Charles Shuttles, The Nielsen Company
10:35 AM
|
Considerations for Design and Data Analysis of Adaptive Superiority/Noninferiority Cardiovascular Trials
Hui Quan, sanofi-aventis; Mingyu Li, Celgene Corporation; Peng-Liang Zhao, sanofi-aventis; Meehyung Cho, sanofi-aventis; Ji Zhang, Sanofi-Aventis; Yujun Wu, Sanofi-Aventis
10:35 AM
|
Maximin Model-Robust Designs for Split Plot Experiments
Byran Jay Smucker, Penn State; Enrique Del Castillo, Penn State; James Rosenberger, Penn State
10:35 AM
|
CTDesignExplorer: An Action Queue--Based Open-Source Simulation Experiment Platform for Evaluating Clinical Trial Designs
Yuanyuan Wang, University of Pittsburgh; Roger Day, University of Pittsburgh; Daniel Normolle, University of Pittsburgh
10:50 AM
|
Sample Size Planning to Obtain Narrow Confidence Intervals for the RMSEA
Ken Kelley, University of Notre Dame; Keke Lai, University of Notre Dame
10:50 AM
|
Design and Trial Operational Considerations for a Phase II Two-Stage Adaptive Trial
Weili He, Merck & Co., Inc.; Madhuja Mallick, Merck & Co., Inc.; Yevgen Tymofyeyev, Merck & Co., Inc.; James A. Bolognese, Cytel Inc.
10:55 AM
|
Challenges in the Conduct of Clinical Trials in the Australasian Region
Val Gebski, University of Sydney
11:05 AM
|
Structural Properties of Optimum Designs and Their Interrelations in Model Identification and Discrimination for 2 ^m Factorial Experiments
Subir Ghosh, University of California, Riverside; Mike Huang, University of California, Riverside
11:05 AM
|
Point and Interval Estimations for Difference of Two Proportions in Incomplete Matched-Paired Data Using Expectation-Maximization Algorithm
Adeniyi J. Adewale, Merck & Co., Inc.; Benjamin B. John, EdgeServe LLC
11:50 AM
|
|